Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-037653
Filing Date
2025-02-27
Accepted
2025-02-27 08:16:08
Documents
6
Effectiveness Date
2025-02-27

Document Format Files

Seq Description Document Type Size
1 S-8 d919693ds8.htm S-8 33096
2 EX-5.1 d919693dex51.htm EX-5.1 8114
3 EX-23.2 d919693dex232.htm EX-23.2 1637
4 EX-FILING FEES d919693dexfilingfees.htm EX-FILING FEES 14181
5 GRAPHIC g919693dsp006.jpg GRAPHIC 12533
6 GRAPHIC g919693g0225064401255.jpg GRAPHIC 1579
  Complete submission text file 0001193125-25-037653.txt   77840
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285309 | Film No.: 25673156
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)